What insurance policy changes affect CPT 82950?

There are 8 tracked policy changes affecting CPT 82950, including updates from Arkansas Blue Cross Blue Shield, Harvard Pilgrim Health Care, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 82950?

Payers that have issued tracked updates for CPT 82950 include: Arkansas Blue Cross Blue Shield, Harvard Pilgrim Health Care, Aetna.

How do I get notified when CPT 82950 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 82950. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 82950?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

82950 Insurance Policy Changes

CPT 82950 is referenced in 8 tracked payer policy changes from Arkansas Blue Cross Blue Shield, Harvard Pilgrim Health Care, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 82950 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact
Policy Criteria Change - Material Amendment
Arkansas Blue Cross Blue Shield·Effective Nov 1, 2026
Arkansas Blue Cross revised coverage criteria for three testing policies effective 11/01/2026: (1) Nongenetic prenatal screening now covers only specific tests (blood type/Rh status, anemia screening, Group B strep, rubella, varicella immunity, and fetal fibronectin for preterm labor symptoms); hCG and salivary hormone testing are no longer covered. (2) CRP/ESR inflammation testing now has condition-specific coverage with defined frequency guidelines; testing without diagnosed inflammatory conditions is not covered. (3) Alpha-1 antitrypsin deficiency testing had codes removed but coverage criteria unchanged. Multiple billing codes were removed across these policies.
High impact
Policy Criteria Change-Material Amendment
Arkansas Blue Cross Blue Shield·Effective Nov 1, 2026
Arkansas Blue Cross revised coverage criteria for three laboratory testing policies effective 11/01/2026: (1) Nongenetic prenatal screening now covers only specific tests (blood type, Rh status, anemia, Group B strep, rubella, varicella immunity, and fetal fibronectin for preterm labor symptoms) with 40 procedure codes removed; (2) CRP/ESR inflammation testing expanded to cover 17 specific inflammatory conditions with defined frequency; (3) Alpha-1 antitrypsin testing removed 2 codes with no coverage criteria changes. Billing teams must identify and deny claims for removed codes and non-covered indications.
High impact
Laboratory Payment Policies: Dec. 1, 2026 updates
Harvard Pilgrim Health Care·Effective Dec 1, 2026
Point32Health/Harvard Pilgrim Health Care is adding new CPT codes to four laboratory testing policies effective December 1, 2026. Billing teams must update their systems to recognize and process these newly covered codes: 0421U for colorectal cancer screening, 82950 for diabetes testing, 87638 for microorganism identification, and 87627, 0600U, 0601U, and 0610U for pathogen panel testing.
High impact
Metabolic monitoring for patients on antipsychotic medications
Harvard Pilgrim Health Care·Identified Sep 8, 2026
Point32Health issued a metabolic monitoring policy for patients on antipsychotic medications, emphasizing annual screening for diabetes and cholesterol levels. The policy provides approved CPT codes for billing glucose, HbA1c, LDL-C, and other cholesterol tests, and requires providers to document baseline metabolic testing at discharge and coordinate care across behavioral health, primary care, and prescribing providers.
High impact
Metabolic monitoring for patients on antipsychotic medications
Harvard Pilgrim Health Care·Identified Jun 26, 2026
Point32Health issued new guidance requiring annual metabolic monitoring (glucose, HbA1c, and cholesterol testing) for all patients on antipsychotic medications across all age groups. Billing teams must use specific approved CPT codes for these screenings and ensure proper documentation, especially for inpatient psychiatric discharges. This policy emphasizes care coordination among providers and includes a referral pathway for Tufts Health Together SMI members.
Medium impact
Teplizumab-mzwv (Tzield) (CPB 1022, reviewed 2025-12-03)
Aetna·Effective Dec 3, 2025
Aetna has established new coverage criteria for teplizumab-mzwv (Tzield), a CD3-directed antibody for Stage 2 type 1 diabetes in patients 8+ years old. The drug requires precertification, endocrinologist prescription, specific autoantibody testing, abnormal glucose tolerance confirmation, and is limited to a single 14-day IV infusion course. Billing teams must implement prior authorization requirements and ensure proper coding for this specialty infusion therapy.
Medium impact
Intermittent Intravenous Insulin Therapy (CPB 0742, reviewed 2025-11-26)
Aetna·Effective Nov 26, 2025
Aetna's updated policy (CPB 0742, effective 2025-11-26) classifies intermittent intravenous insulin therapy and related diagnostic testing as experimental and investigational, making these services non-covered. Billing teams must deny claims for pulsatile intravenous insulin therapy, hepatic activation therapy, and associated glucose/potassium monitoring tests when billed under the listed CPT/HCPCS codes. Exception: standard insulin infusions for diabetic ketoacidosis or hyperosmolar coma remain covered.
Medium impact
Intermittent Intravenous Insulin Therapy (CPB 0742, reviewed 2026-10-16)
Aetna·Identified Oct 19, 2026
Aetna's Clinical Policy Bulletin 0742 (reviewed 2026-10-16) classifies intermittent intravenous insulin therapy and related diagnostic tests as experimental, investigational, or unproven. Specific CPT codes (82947, 82948, 82950, 84132, 84133, 84540) and HCPCS codes (G9147, J1811–J1815, J1817, S5550–S5571) are not covered when performed in the context of this therapy. The policy explicitly excludes insulin infusions for diabetic ketoacidosis and hyperosmolar coma from this non-coverage determination.

All billing codes J3590 C9399 J3490 99213 99214 99212

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Policy Criteria Change - Material Amendment

Policy Criteria Change-Material Amendment

Laboratory Payment Policies: Dec. 1, 2026 updates

Metabolic monitoring for patients on antipsychotic medications

Metabolic monitoring for patients on antipsychotic medications

Teplizumab-mzwv (Tzield) (CPB 1022, reviewed 2025-12-03)

Intermittent Intravenous Insulin Therapy (CPB 0742, reviewed 2025-11-26)

Intermittent Intravenous Insulin Therapy (CPB 0742, reviewed 2026-10-16)